Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Pfizer prepares new class of MMP inhibitors with hydroxamic acid structure

Sep. 13, 1999

Arava approved in Europe for rheumatoid arthritis

Sep. 10, 1999

Recently issued U.S. patent covers Searle's newest p38 MAP kinase inhibitors

Sep. 10, 1999

Rofecoxib, a new COX-2 inhibitor, effective against fever in monkeys and humans

Sep. 9, 1999

MCP-1/RANTES inhibitors in early development at AstraZeneca

Sep. 9, 1999

MGI Pharma begins to copromote Azulfidine EN-tabs in RA

Sep. 8, 1999

BioHy study initiated for treatment of osteoarthritis of the knee

Sep. 7, 1999

Hydroxamic and carboxylic acid-based MMP/TNF-alpha inhibitors center of focus at Darwin

Sep. 6, 1999

Abbott continues to improve on cell adhesion inhibitors

Sep. 6, 1999

Darwin's new MMP inhibitors useful for degenerative diseases, cancer, etc.

Sep. 3, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...